CLYM Insider Trading Activity and SEC Form 4 Filings
CLYM insider trading summary
Over the past 12 months, insiders at Climb Bio, Inc. (CLYM) reported 21 open-market purchases worth $5.5M by 7 insiders and 4 sales worth $2.3M by 2 insiders on SEC Form 4. Net insider buying was $3.2M.
Latest CLYM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Stephen Basil Thomas | Insider | Sell | $1.4M (100,000 @ $13.67) |
| Jun 29, 2026 | Aoife Brennan | President and CEO | Sell | $407K (30,902 @ $13.17) |
| Feb 13, 2026 | Stephen Basil Thomas | Insider | Sell | $58K (10,000 @ $5.81) |
| Feb 12, 2026 | Stephen Basil Thomas | Insider | Sell | $471K (90,000 @ $5.23) |
| Jan 5, 2026 | RA Capital Nexus Fund II, L.P. | Director | Buy | $25K (7,111 @ $3.50) |
| Jan 5, 2026 | RA Capital Healthcare Fund LP | Director | Buy | $25K (7,111 @ $3.50) |
| Jan 5, 2026 | Rajeev M. Shah | Director | Buy | $25K (7,111 @ $3.50) |
| Jan 5, 2026 | RA Capital Nexus Fund, L.P. | Director | Buy | $25K (7,111 @ $3.50) |
| Jan 5, 2026 | Ra Capital Management, L.P. | Insider | Buy | $25K (7,111 @ $3.50) |
| Jan 5, 2026 | RA Capital Nexus Fund III, L.P. | Director | Buy | $25K (7,111 @ $3.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.